Inhibition of monoamine oxidase by selected C5- and C6-substituted isatin analogues.
Clarina I Manley-King, Jacobus J Bergh, Jacobus P Petzer
文献索引:Bioorg. Med. Chem. 19 , 261-74, (2011)
全文:HTML全文
摘要
Previous studies have shown that (E)-5-styrylisatin and (E)-6-styrylisatin are reversible inhibitors of human monoamine oxidase (MAO) A and B. Both homologues are reported to exhibit selective binding to the MAO-B isoform with (E)-5-styrylisatin being the most potent inhibitor. To further investigate these structure-activity relationships (SAR), in the present study, additional C5- and C6-substituted isatin analogues were synthesized and evaluated as inhibitors of recombinant human MAO-A and MAO-B. With the exception of 5-phenylisatin, all of the analogues examined were selective MAO-B inhibitors. The C5-substituted isatins exhibited higher binding affinities to MAO-B than the corresponding C6-substituted homologues. The most potent MAO-B inhibitor, 5-(4-phenylbutyl)isatin, exhibited an IC(50) value of 0.66nM, approximately 13-fold more potent than (E)-5-styrylisatin and 18,500-fold more potent than isatin. The most potent MAO-A inhibitor was found to be 5-phenylisatin with an IC(50) value of 562nM. The results document that substitution at C5 with a variety of substituents is a general strategy for enhancing the MAO-B inhibition potency of isatin. Possible binding orientations of selected isatin analogues within the active site cavities of MAO-A and MAO-B are proposed.Copyright © 2010. Published by Elsevier Ltd.
相关化合物
相关文献:
2014-12-01
[Regul Toxicol Pharmacol 70 Suppl 1 , S2-14, (2014)]
2009-12-01
[Mutat. Res. 671(1-2) , 13-9, (2009)]
2011-03-01
[Biomarkers 16(2) , 120-8, (2011)]
2011-02-01
[Arch. Toxicol. 85(2) , 127-33, (2011)]
2011-07-01
[Cancer Epidemiol. Biomarkers Prev. 20(7) , 1524-36, (2011)]